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Objectives: The use of tenofovir is highly associated with the emergence of mutation K65R, which confers
broad resistance to nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTIs), especially when
tenofovir is combined with other NRTIs also selecting for K65R. Although recent HIV-1 treatment guidelines dis-
couraging these combinations resulted in reduced K65R selection with tenofovir, updated information on the
impact of currently recommended regimens on the population selection rate of K65R is presently lacking.
Methods: In this study, we evaluated changes over time in the selection rate of resistance mutation K65R in a large
population of 2736 HIV-1-infected patients failing combination antiretroviral treatment between 2002 and 2010.
Results: The K65R resistance mutation was detected in 144 patients, a prevalence of 5.3%. A large majority of
observed K65R cases were explained by the use of tenofovir, reflecting its wide use in clinical practice. However,
changing patterns over time in NRTIs accompanying tenofovir resulted in a persistent decreasing probability
of K65R selection by tenofovir-based therapy. The currently recommended NRTI combination tenofovir/
emtricitabine was associated with a low probability of K65R emergence. For any given dual NRTI combination
including tenofovir, higher selection rates of K65R were consistently observed with a non-nucleoside reverse
transcriptase inhibitor than with a protease inhibitor as the third agent.
Discussion: Our finding of a stable time trend of K65R despite elevated use of tenofovir illustrates increased
potency of current HIV-1 therapy including tenofovir.
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Introduction
The lysine-to-arginine mutation at position 65 (K65R) in HIV-1
reverse transcriptase confers broad cross-resistance to nucleoside/
nucleotide analogue reverse transcriptase inhibitors (NRTIs). K65R
is primarily selected by tenofovir and to a lesser extent by
abacavir and didanosine. An initial rise in K65R population preva-
lence was observed following the increased clinical use of tenofovir
dating to 2001.1,2 However, we previously reported a strong
decline in K65R incidence by 2005 despite a continuously increas-
ing number of patients treated and subsequently failing with teno-
fovir.3 The highest rate of K65R selection was observed when
tenofovir was co-administered with didanosine, and the K65R inci-
dence trend was significantly correlated over time with the
number of failures including this drug combination, which is no
longer recommended. Although changes in HIV-1 treatment
guidelines strongly reduced the probability of K65R selection,
updated information on the impact of currently recomm-
ended co-formulations of tenofovir/emtricitabine and abacavir/
lamivudine on K65R selection at population level is presently
lacking.4,5 This information is imperative to identify drug combina-
tions that can further minimize K65R emergence.
Methods
This study determined the population rate of the K65R resistance muta-
tion and factors associated with observed changes in K65R selection by
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evaluating K65R emergence over time in a Portuguese HIV-infected
drug-resistant cohort between 2002 and 2010.3 We collected 3820
viral isolates that were obtained from genotypic resistance testing of
2736 HIV-1-infected patients failing combination antiretroviral treat-
ment (cART) containing an NRTI. For each patient, the first occurrence
of K65R was considered, excluding subsequent resistance and treat-
ment information from the analysis. First, an association with drug regi-
mens including tenofovir, didanosine or abacavir was identified by
determining their distribution in the number of observed K65R cases.
The analysis focused on dual NRTI regimens with a protease inhibitor
(PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI) as
a third agent, and with lamivudine or emtricitabine in case of
tenofovir/abacavir and tenofovir/didanosine. Second, to capture their
impact on K65R selection at the population level, we calculated for
each regimen the selection rate, defined as the number of regimen fail-
ures with K65R over the number of regimen failures, and the failing rate,
defined as the number of regimen failures over the total number of
cART failures. Temporal changes in parameters were plotted using a
sliding window approach with a window size of 12 months that
shifted 1 month in time. The Mann–Whitney U-test was performed
for statistical comparison between K65R presence and continuous vari-
ables and Fisher’s exact test for categorical variables. ORs quantified
direction and magnitude of the association. The level of statistical
significance was set at 5%.
Results
The mutation K65R was detected in 144 patients (5.3%; CI
4.5%–6.2%), and a large majority of these patients (110
patients; 76%) received tenofovir at the time of detection
(Table 1). Other NRTIs were lamivudine (34%), emtricitabine
(32%), didanosine (31%), abacavir (14%), stavudine (12%)
and zidovudine (8%). K65R patients were primarily treated
with dual NRTI combinations (130 patients; 90%), which were
more often accompanied by an NNRTI (84%) than by a PI
(15%) (P,0.01), and less frequently with triple NRTI cART
(7.6%). Table 1 shows the most prevalent NRTI combinations
among K65R patients, accounting for 131 observations (91%).
When only tenofovir regimens were considered, tenofovir was
mostly administered as dual NRTI pair (99 patients; 90%)
with an NNRTI (88%) or a PI (13%) (P,0.01) as the third
agent, but the distribution of the accompanying NRTI
Table 1. K65R selection by NRTI combinations including tenofovir, abacavir or didanosine is shown for 131 of 144 K65R patients.
Failures K65R SR (%) CR (%) P OR (CI)
TDF 1267 110 8.7 76.4 ,0.001 5.6 (3.8–8.1)
TDF/ddI 101 28 27.7 19.4 ,0.001 10.05 (6.33–16.04)
+NNRTI 47 20 42.6 13.9 ,0.001 17.27 (9.67–30.88)
+PI 33 2 6.1 1.4 0.640 1.46 (0.35–6.15)
+3TC or FTC 12 5 41.7 3.5 ,0.001 18.82 (5.91–60.15)
+3TC or FTC+PI 7 1 14.3 0.7 0.293 3.2 (0.40–25.80)
TDF/3TC 186 24 12.9 16.7 ,0.001 3.79 (2.38–6.03)
+NNRTI 95 21 22.1 14.6 ,0.001 7.67 (4.59–12.81)
+PI 80 1 1.3 0.7 0.264 0.27 (0.03–1.97)
TDF/FTC 561 43 7.7 29.9 ,0.001 2.17 (1.46–3.16)
+NNRTI 250 37 14.8 25.7 ,0.001 5.01 (3.27–7.54)
+PI 297 6 2.0 4.2 0.027 0.41 (0.15–0.93)
TDF/ABC 103 10 9.7 6.9 0.014 2.42 (1.11–4.76)
+NNRTI 11 6 54.5 4.2 ,0.001 31.82 (7.98–133.40)
+PI 50 2 4.0 1.4 0.650 0.87 (0.10–3.38)
+3TC/FTC 2 0 0.0 0.0 0.760 0 (-)
+3TC/FTC+PI 28 1 3.6 0.7 0.872 0.75 (0.02–4.54)
+3TC/FTC+NNRTI 6 1 16.7 0.7 0.206 5.12 (0.10–46.27)
ddI/d4T (no TDF) 260 14 5.4 9.7 0.340 1.29 (0.67–2.28)
+NNRTI 109 9 8.3 6.3 0.043 2.18 (0.95–4.42)
+PI 97 3 3.1 2.1 0.800 0.67 (0.14–2.07)
ABC/3TC (no TDF) 138 7 5.1 4.9 0.522 1.21 (0.47–2.64)
+NNRTI 51 5 9.8 3.5 0.051 2.66 (0.81–6.79)
+PI 84 2 2.4 1.4 0.586 0.53 (0.06–2.01)
TDF, tenofovir; ddI, didanosine; 3TC, lamivudine; FTC, emtricitabine; ABC, abacavir; d4T, stavudine.
For each regimen, the number of therapy failures and K65R cases among the 2736 study patients are reported. The selection rate (SR), defined as the
number of K65R cases selected by a regimen over the number of failures with this regimen, and the contribution rate (CR), defined as the number of
K65R cases selected by a regimen over the total of 144 K65R cases observed, are calculated. P values are calculated to test for an association of the
regimen with K65R presence (2×2 contingency table), and ORs with CIs indicate the magnitude of the association.
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substantially changed over time (Figure 1). Initially, K65R selec-
tion was largely explained by the use of tenofovir/didanosine,
accounting for 28 cases (19%, peaking at 55% in 2003), and
tenofovir/lamivudine, accounting for 24 cases (17%, peaking
at 53% in 2005). However, their contribution to observed
K65R decreased dramatically over time, mainly in favour of
tenofovir/emtricitabine. This regimen explained 43 K65R cases
(30%) and contributed to more than 65% of K65R in 2010.
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Figure 1. Two density plots of distributions are shown using a sliding window of 12 months with 1 month shifts in time. Calendar year shown spans
the time period January to December of that calendar year. Top: different NRTI regimens present among the 144 K65R patients. Bottom:
accompanying backbone NRTI among patients failing cART including tenofovir. These trends most likely illustrate changes in treatment guidelines.
The predominant prevalence of emtricitabine resulted from the wide use of this effective regimen, recommended for first-line cART. ABC, abacavir;
3TC, lamivudine; TDF, tenofovir; FTC, emtricitabine; d4T, stavudine; ddI, didanosine. This figure appears in colour in the online version of JAC and in
black and white in the print version of JAC.
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Furthermore, K65R was detected in 34 (24%) patients while re-
ceiving non-tenofovir cART, only three of whom had previous
tenofovir experience. Stavudine/didanosine (14 patients; 41%)
initially prevailed but was replaced by abacavir/lamivudine
(seven patients; 21%) in more recent years. No time trends
were observed in NNRTI versus PI distributions.
Next, we calculated the impact of these drug combinations
on K65R selection at population level and the prevalence
among therapy failures (Table 1). Tenofovir use was high (41%)
among the 2736 patients, primarily as part of an NRTI pair
(81%) and more often with a PI (65%) than with an NNRTI
(35%) as the third agent. The lowest selection rates were
observed for tenofovir combined with emtricitabine or abacavir,
while non-tenofovir regimens displayed comparable selection
rates. Selection rates of dual NRTI regimens were higher with
the inclusion of an NNRTI (8.1%) than with a PI (1.2%)
(P,0.01). This discrepancy between NNRTIs (18.1%) and PIs
(2.2%) (P,0.01) strongly increased when only dual NRTI regi-
mens including tenofovir were considered. In line with the
recommended use of tenofovir for first-line cART,4 the proportion
of failing therapies including tenofovir continuously increased
over time. The failing rate of tenofovir-including regimens
changed from 16.2% in 2002–04, through 38.1% in 2005–07
to 59.9% in 2008–10 (Figure S1, available as Supplementary
data at JAC Online). However, the previously observed fall in
K65R incidence in 2005 was followed by a fluctuating but
stable incidence trend (Figure S2, available as Supplementary
data at JAC Online), indicating that, over time, the tenofovir-
based cART selected less for the K65R mutation. The resulting
selection rate of tenofovir-including regimens was 15.8% in
2002–04, 8.8% in 2005–07 and 5.7% in 2008–10 (Figure S1,
available as Supplementary data at JAC Online). When the
number of K65R cases was normalized for the observed time
on tenofovir therapy, we observed a similar reduction in selection
by tenofovir of, respectively, 17.7, 6.2 and 2.9 cases per 100
patient-years for the three time periods. Among therapy failures,
tenofovir was in recent years increasingly co-administered in
regimens displaying lower K65R selection rates, more specifically
tenofovir/emtricitabine, thereby replacing regimens with high
selection rates, in particular combinations of tenofovir with
didanosine or lamivudine (Table 1 and Figure 1).
Finally, observed changing patterns in regimens also affected
characteristics of K65R patients. Resistance mutations in reverse
transcriptase were previously associated with the presence of
K65R.3 As tenofovir was increasingly administered in the pres-
ence of emtricitabine (47%) or lamivudine (27%), co-occurrence
of K65R with mutation M184V increased up to 77% in 2010. Nu-
cleoside analogue mutations (A62V, F77L, F116Y or Q151M) in
K65R patients prevailed at a low level (21%) and decreased
with time. NNRTI mutations (Y181C or K103N) occurred in 67%
of K65R cases with no clear time trends (data not shown). Zidov-
udine was rarely included among tenofovir regimens (15%) but
this increased over time, reaching a maximum of 22% in 2008.
Consistent with the antagonistic effect between K65R and thymi-
dine analogue mutations (TAMs),3,6,7 K65R incidence inversely
correlated with the trend in zidovudine accompanying tenofovir
(P¼0.039, r¼20.27). Although our dataset displayed overall
decreasing prevalence of zidovudine use or TAMs and mainly
first-line use of tenofovir, K65R occurred equally often in first-
(36%) or second-line (34%) treatment, with no clear trends
over time (data not shown). Regression analyses indicated an
increase of 49 days in time on therapy before K65R detection
with every additional calendar year (P¼0.002). With respect to
viral genomic diversity,8 patients were predominantly infected
with subtypes B (34.5%) and G (36%) showing equal tenofovir
experience (50%). K65R prevalence did not differ between
subtype B (2.9%) and subtype G (4.1%) (P¼0.24).
Discussion
Decreasing population trends of drug resistance in antiretroviral-
experienced HIV-1 patients have been attributed to more
effective and better tolerated cART.9,10 Antiretroviral resistance
was primarily evaluated at the level of the drug class, but infor-
mation on population and temporal dynamics of individual drug
resistance mutations is warranted as new antiretrovirals enter
clinical practice and new regimens become recommended. We
have previously reported the existence of strong combination-
dependent effects on K65R selection due to inferior tenofovir
regimens. In this study, we evaluated population selection
rates of K65R by currently recommended drug regimens in a
large antiretroviral-experienced patient population. K65R was
highly associated with the use of tenofovir, in agreement with
our previous analysis.3 Over time, K65R incidence remained rela-
tively stable despite elevated tenofovir and abacavir use. Our
data suggest that this discrepancy is largely explained by a
strong and persistent decline in K65R selection rate of tenofovir
due to changed treatment guidelines and the availability of teno-
fovir in co-formulation with emtricitabine. Although tenofovir/
emtricitabine selected for most cases, this regimen displayed
one of the lowest K65R selection rates and was predominant
among therapy failures due to its wide use in current cART.
Another regimen with low selection rates for K65R was
abacavir/lamivudine, but increased use in recent years resulted
in several K65R-related failures in patients naive to tenofovir. Re-
markably, the magnitude of K65R selection was significantly
higher with the inclusion of an NNRTI than with a PI. In conclu-
sion, our findings illustrate increased potency of current tenofovir
regimens for HIV-1 treatment.
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